BiotechTube

PRGN-3005 UltraCAR-T cells + PRGN-3005 UltraCAR-T cells

Phase 1Active
0 watching 0 views this week💤 Quiet
28
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Platinum-Resistant Fallopian Tube Carcinoma

Conditions

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC V8, Stage III Ovarian Cancer AJCC V8, Stage III Primary Peritoneal Cancer AJCC V8, Stage IIIA Fallopian Tube Cancer AJCC V8, Stage IIIA Ovarian Cancer AJCC V8, Stage IIIA Primary Peritoneal Cancer AJCC V8, Stage IIIA1 Fallopian Tube Cancer AJCC V8, Stage IIIA1 Ovarian Cancer AJCC V8, Stage IIIA2 Fallopian Tube Cancer AJCC V8, Stage IIIA2 Ovarian Cancer AJCC V8, Stage IIIB Fallopian Tube Cancer AJCC V8, Stage IIIB Ovarian Cancer AJCC V8, Stage IIIB Primary Peritoneal Cancer AJCC V8, Stage IIIC Fallopian Tube Cancer AJCC V8, Stage IIIC Ovarian Cancer AJCC V8, Stage IIIC Primary Peritoneal Cancer AJCC V8, Stage IV Fallopian Tube Cancer AJCC V8, Stage IV Ovarian Cancer AJCC V8, Stage IV Primary Peritoneal Cancer AJCC V8, Stage IVA Fallopian Tube Cancer AJCC V8, Stage IVA Ovarian Cancer AJCC V8, Stage IVA Primary Peritoneal Cancer AJCC V8, Stage IVB Fallopian Tube Cancer AJCC V8, Stage IVB Ovarian Cancer AJCC V8, Stage IVB Primary Peritoneal Cancer AJCC V8

Trial Timeline

Apr 30, 2019 → Nov 15, 2028

NCT ID
NCT03907527

About PRGN-3005 UltraCAR-T cells + PRGN-3005 UltraCAR-T cells

PRGN-3005 UltraCAR-T cells + PRGN-3005 UltraCAR-T cells is a phase 1 stage product being developed by Precigen for Platinum-Resistant Fallopian Tube Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT03907527. Target conditions include Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma.

Hype Score Breakdown

Clinical
10
Activity
5
Company
5
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03907527Phase 1Active

Competing Products

16 competing products in Platinum-Resistant Fallopian Tube Carcinoma

See all competitors
ProductCompanyStageHype Score
Niraparib + AnlotinibSun PharmaceuticalPhase 2
52
E7050 + CetuximabEisaiPhase 1/2
41
PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd + PLD 40mg/m2 ivgtt q4wJiangsu Hengrui MedicinePhase 2
52
Batiraxcept + DurvalumabAstraZenecaPhase 1/2
41
olaparib+cediranib combination therapy + durvalumab + olaparib combination therapy + durvalumab + chemotherapy treatment + durvalumab + tremelimumab + chemotherapy treatment + durvalumab + tremelimumab + paclitaxel treatment + durvalumab +chemotherapy treatmentAstraZenecaPhase 2
52
Nemvaleukin and Pembrolizumab Combination + Pembrolizumab + Nemvaleukin + Pegylated Liposomal Doxorubicin (PLD) + Paclitaxel + Topotecan + GemcitabineMerckPhase 3
77
CRS-207 + Epacadostat + PembrolizumabIncytePhase 1/2
38
Rina-S + Paclitaxel + Topotecan + Pegylated liposomal doxorubicin (PLD) + GemcitabineGenmabPhase 3
74
Bevacizumab + Irinotecan SucrosofateIpsenPhase 2
49
Gemcitabine + N-803 + M-CENKImmunityBioPhase 2
49
Drug Product De-TIL-0255Nurix TherapeuticsPhase 1
28
Pegylated Liposomal Doxorubicin + SL-172154 + Mirvetuximab + SL-172154Shattuck LabsPhase 1
25
CTIM-76Context TherapeuticsPhase 1
25
LorigerlimabMacroGenicsPhase 2
44
olvimulogene nanivacirepvec + Platinum chemotherapy: carboplatin (preferred) or cisplatin + Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin + Bevacizumab (or biosimilar)GeneluxPhase 3
69
PHI-101 administrationiBioPhase 1
25

Other Products from Precigen

Zopapogene imadenovec (Zopa)Approved
80
PRGN-2009 plus Pembrolizumab + Pembrolizumab alonePhase 2
47
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2Phase 1/2
36
AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High DosePhase 1/2
36
INXN-4001Phase 1
28